A Significant Milestone for Neuroblastoma Research In a promising development for pediatric oncology, UTR Therapeutics Inc. has officially announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation to its therapeutic candidate, UTRX-MYCN-M1. This candidate is currently being developed for the treatment of neuroblastoma, a rare…